StockNews.AI
CGEN
StockNews.AI
182 days

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

1. Compugen will release Q4 and full year 2024 results on March 4, 2025. 2. A live conference call will follow the results announcement for corporate updates. 3. Compugen has two drug candidates in Phase 1 development targeting solid tumors. 4. AstraZeneca is developing Rilvegostomig using Compugen's anti-TIGIT antibody technology. 5. Compugen's platform identifies new drug targets for cancer immunotherapy.

Earnings
+0.68%Current Return
VS
+0.32%S&P 500
$2.2202/18 07:07 AM EDTEvent Start
$2.23502/19 02:01 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming results are standard procedure, unlikely to cause unexpected movements.

How important is it?

Earnings results may present insights into financial health but are typically routine.

Why Short Term?

Immediate focus on quarterly results may impact short-term investor sentiment.

Related Companies

AZNGILD
, /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live webcast, a replay will be available on the Company's website. About CompugenCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact:Yvonne Naughton, Ph.D.VP, Head of Investor Relations, and Corporate CommunicationsEmail: [email protected]Tel: +1 (628) 241-0071  SOURCE Compugen Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News